Literature DB >> 27081845

Serum Procalcitonin as a Biomarker for the Prediction of Bacterial Exacerbation and Mortality in Severe COPD Exacerbations Requiring Mechanical Ventilation.

Begum Ergan1, Ahmet Altay Şahin, Arzu Topeli.   

Abstract

BACKGROUND: Procalcitonin (PCT) is being used as a marker of bacterial infections. Although there are several studies showing the diagnostic yield of PCT to differentiate bacterial involvement in chronic obstructive pulmonary disease exacerbations (COPDE), the prognostic yield of PCT in severe COPDE has been studied less.
OBJECTIVES: The primary aim was to determine whether the level of serum PCT at admission in severe COPDE serves as a prognostic biomarker for hospital mortality. The secondary aim was to determine the role of PCT in identifying a bacterial exacerbation.
METHODS: A total of 63 COPDE patients (median age 71 years; male 58.7%) were retrospectively analyzed from our intensive care unit database.
RESULTS: The hospital mortality rate was 23.8%. Admission PCT levels were higher in patients who died during hospitalization (0.66 vs. 0.17 ng/ml; p = 0.014). This association between hospital mortality and serum PCT level remained significant in a multivariate analysis; for every 1 ng/ml increase in PCT level, hospital mortality increased 1.85 times (odds ratio; 95% confidence interval: 1.07-3.19; p = 0.026). The optimal admission PCT threshold was 0.25 ng/ml in order to discern patients who had bacterial exacerbation with a sensitivity of 63%, a specificity of 67%, and a negative predictive value of 80%. The negative predictive value increased to 89% when both the admission and follow-up PCT levels remained <0.25 ng/ml.
CONCLUSION: This study shows that admission PCT levels have a prognostic importance in estimating hospital mortality among patients with severe COPDE. A PCT level <0.25 ng/ml at the time of admission and during follow-up is suggestive of the absence of a bacterial cause of COPDE.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27081845     DOI: 10.1159/000445440

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  11 in total

1.  Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial.

Authors:  Cheng-Liang Qian; Rong Fan
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

2.  Optimal cut-off value of serum procalcitonin in predicting bacterial infection induced acute exacerbation in chronic obstructive pulmonary disease: A prospective observational study.

Authors:  Yan-Ping Ye; Hang Zhao; Tao Kang; Li-Hua Zhao; Ning Li; Jing Chen; Xiao-Xia Peng
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

Review 3.  Diagnostic Accuracy of Liquid Biomarkers in Airway Diseases: Toward Point-of-Care Applications.

Authors:  Vivianne Landry; Patrick Coburn; Karen Kost; Xinyu Liu; Nicole Y K Li-Jessen
Journal:  Front Med (Lausanne)       Date:  2022-06-06

4.  Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis.

Authors:  George Hoult; David Gillespie; Tom M A Wilkinson; Mike Thomas; Nick A Francis
Journal:  BMC Pulm Med       Date:  2022-05-13       Impact factor: 3.320

5.  Clinical Differences between Eosinophilic and Noneosinophilic Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study.

Authors:  Guangming Dai; Yajuan Ran; Jiajia Wang; Xingru Chen; Junnan Peng; Xinglong Li; Huojin Deng; Min Xiao; Tao Zhu
Journal:  Mediators Inflamm       Date:  2020-11-12       Impact factor: 4.711

6.  Comparison of CRP, Procalcitonin, Neutrophil Counts, Eosinophil Counts, sTREM-1, and OPN between Pneumonic and Nonpneumonic Exacerbations in COPD Patients.

Authors:  Shan Mou; Wei Zhang; Yan Deng; Zhijun Tang; Depeng Jiang
Journal:  Can Respir J       Date:  2022-03-31       Impact factor: 2.409

7.  A Simple Scoring System to Differentiate Bacterial from Viral Infections in Acute Exacerbations of COPD Requiring Hospitalization.

Authors:  Agustín Ruiz-González; Eduardo Sáez-Huerta; Montserrat Martínez-Alonso; Albert Bernet-Sánchez; José M Porcel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-04-08

Review 8.  The Use of Serum Procalcitonin as a Diagnostic and Prognostic Biomarker in Chronic Obstructive Pulmonary Disease Exacerbations: A Literature Review Update.

Authors:  Nikolaos-Dimitrios Pantzaris; Diamantina-Xanthi Spilioti; Aikaterini Psaromyalou; Ioanna Koniari; Dimitrios Velissaris
Journal:  J Clin Med Res       Date:  2018-06-04

Review 9.  Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmornary Disease? What Do We Need to Add?

Authors:  Maria Montes de Oca; Maria Eugenia Laucho-Contreras
Journal:  Med Sci (Basel)       Date:  2018-06-14

Review 10.  A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine.

Authors:  Anna Maria Azzini; Romolo Marco Dorizzi; Piersandro Sette; Marta Vecchi; Ilaria Coledan; Elda Righi; Evelina Tacconelli
Journal:  Ann Transl Med       Date:  2020-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.